Sartorius Stedim Revenue vs. Cash Per Share
| 56S1 Stock | EUR 183.30 1.10 0.60% |
For Sartorius Stedim profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sartorius Stedim to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sartorius Stedim Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sartorius Stedim's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sartorius Stedim Biotech over time as well as its relative position and ranking within its peers.
Sartorius |
Sartorius Stedim Biotech Cash Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sartorius Stedim's current stock value. Our valuation model uses many indicators to compare Sartorius Stedim value to that of its competitors to determine the firm's financial worth. Sartorius Stedim Biotech is rated below average in revenue category among its peers. It is rated below average in cash per share category among its peers . The ratio of Revenue to Cash Per Share for Sartorius Stedim Biotech is about 1,962,191,011 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sartorius Stedim's earnings, one of the primary drivers of an investment's value.Sartorius Revenue vs. Competition
Sartorius Stedim Biotech is rated below average in revenue category among its peers. Market size based on revenue of Medical Instruments & Supplies industry is presently estimated at about 76.11 Billion. Sartorius Stedim holds roughly 3.49 Billion in revenue claiming about 5% of all equities under Medical Instruments & Supplies industry.
Sartorius Cash Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Sartorius Stedim |
| = | 3.49 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Sartorius Stedim |
| = | 1.78 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Sartorius Cash Per Share Comparison
Sartorius Stedim is rated fifth in cash per share category among its peers.
Sartorius Stedim Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sartorius Stedim, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sartorius Stedim will eventually generate negative long term returns. The profitability progress is the general direction of Sartorius Stedim's change in net profit over the period of time. It can combine multiple indicators of Sartorius Stedim, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. SARTOR STED operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. It employs 8200 people.
Sartorius Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sartorius Stedim. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sartorius Stedim position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sartorius Stedim's important profitability drivers and their relationship over time.
Use Sartorius Stedim in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sartorius Stedim position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sartorius Stedim will appreciate offsetting losses from the drop in the long position's value.Sartorius Stedim Pair Trading
Sartorius Stedim Biotech Pair Trading Analysis
The ability to find closely correlated positions to Sartorius Stedim could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sartorius Stedim when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sartorius Stedim - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sartorius Stedim Biotech to buy it.
The correlation of Sartorius Stedim is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sartorius Stedim moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sartorius Stedim Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sartorius Stedim can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sartorius Stedim position
In addition to having Sartorius Stedim in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Providers Thematic Idea Now
Insurance Providers
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sartorius Stock
To fully project Sartorius Stedim's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sartorius Stedim Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sartorius Stedim's income statement, its balance sheet, and the statement of cash flows.